Nuvation Bio Inc (NUVB) concluded trading on Wednesday at a closing price of $2.05, with 4.69 million shares of worth about $9.6 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -25.72% during that period and on July 02, 2025 the price saw a gain of about 5.67%. Currently the company’s common shares owned by public are about 338.84M shares, out of which, 226.12M shares are available for trading.
Stock saw a price change of 9.04% in past 5 days and over the past one month there was a price change of -12.39%. Year-to-date (YTD), NUVB shares are showing a performance of -29.79% which decreased to -22.93% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.54 but also hit the highest price of $3.97 during that period. The average intraday trading volume for Nuvation Bio Inc shares is 5.48 million. The stock is currently trading -0.77% below its 20-day simple moving average (SMA20), while that difference is down -4.57% for SMA50 and it goes to -12.26% lower than SMA200.
Nuvation Bio Inc (NYSE: NUVB) currently have 338.84M outstanding shares and institutions hold larger chunk of about 48.22% of that.
The stock has a current market capitalization of $697.54M and its 3Y-monthly beta is at 1.33. It has posted earnings per share of -$2.34 in the same period. It has Quick Ratio of 9.01 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NUVB, volatility over the week remained 7.37% while standing at 10.35% over the month.
Analysts are in expectations that Nuvation Bio Inc (NUVB) stock would likely to be making an EPS of -0.14 in the current quarter, while forecast for next quarter EPS is -0.16 and it is -0.59 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.14 which is -0.14 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.85 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 69.19% while it is estimated to increase by 8.57% in next year. EPS is likely to grow at an annualized rate of 38.04% for next 5-years, compared to annual growth of -49.14% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citizens JMP on April 23, 2025 offering a Mkt outperform rating for the stock and assigned a target price of $6 to it. Coverage by Jefferies stated Nuvation Bio Inc (NUVB) stock as a Buy in their note to investors on March 27, 2024, suggesting a price target of $10 for the stock. On March 26, 2024, BTIG Research Upgrade their recommendations, while on January 06, 2023, Jefferies Downgrade their ratings for the stock with a price target of $2. Stock get a Neutral rating from BTIG Research on August 02, 2022.
